The clinical trial will study PEX010, Filament’s botanical psilocybin drug candidate VANCOUVER, BC, March 15, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical–stage natural psychedelic drug development company, today announced approval from the United States Food and Drug Administration (FDA) for a clinical trial at the University of…


Previous articleCORRECTION — BetterLife Closes $1,857,143 of Private Placement
Next articleField Trip Health & Wellness to Close Clinics in 5 Locations